T. Rowe Price Associates
ASPN icon

T. Rowe Price Associates’s Aspen Aerogels ASPN Stock Holding History

T. Rowe Price Associates’s Portfolio ASPN Stock Details ASPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$827K Buy
130,300
+23,000
+21% +$113K ﹤0.01% 2412
2026
Q1 		$367K Buy
107,300
+9,001
+9% +$30.3K ﹤0.01% 2576
2025
Q4 		$279K Buy
98,299
+21,673
+28% +$112K ﹤0.01% 2675
2025
Q3 		$534K Buy
76,626
+5,749
+8% +$40.5K ﹤0.01% 2329
2025
Q2 		$420K Buy
70,877
+4,502
+7% +$25.9K ﹤0.01% 2382
2025
Q1 		$425K Buy
66,375
+23,924
+56% +$231K ﹤0.01% 2318
2024
Q4 		$505K Buy
42,451
+11,688
+38% +$199K ﹤0.01% 2274
2024
Q3 		$852K Buy
30,763
+8,877
+41% +$222K ﹤0.01% 2040
2024
Q2 		$522K Buy
21,886
+7,306
+50% +$171K ﹤0.01% 2176
2024
Q1 		$257K Buy
14,580
+1,938
+15% +$28.6K ﹤0.01% 2507
2023
Q4 		$200K Buy
12,642
+674
+6% +$6.96K ﹤0.01% 2546
2023
Q3 		$103K Buy
11,968
+1,280
+12% +$9.09K ﹤0.01% 2662
2023
Q2 		$85K Buy
+10,688
New +$74.4K ﹤0.01% 2722
2022
Q1 		– Sell
-375,968
Closed -$18.7M – 2979
2021
Q4 		$18.7M Sell
375,968
-76,862
-17% -$4.05M ﹤0.01% 1300
2021
Q3 		$20.8M Sell
452,830
-54,254
-11% -$2.15M ﹤0.01% 1286
2021
Q2 		$15.2M Sell
507,084
-89,683
-15% -$1.83M ﹤0.01% 1362
2021
Q1 		$12.1M Buy
596,767
+3,458
+0.6% +$72.9K ﹤0.01% 1363
2020
Q4 		$9.9M Buy
593,309
+12,743
+2% +$168K ﹤0.01% 1352
2020
Q3 		$6.36M Buy
+580,566
New +$4.59M ﹤0.01% 1375
2016
Q4 		– Sell
-2,721,240
Closed -$16.2M – 2549
2016
Q3 		$16.2M Sell
2,721,240
-22,500
-0.8% -$113K ﹤0.01% 1202
2016
Q2 		$13.6M Sell
2,743,740
-3,240
-0.1% -$14.2K ﹤0.01% 1221
2016
Q1 		$12.4M Buy
2,746,980
+537,410
+24% +$2.44M ﹤0.01% 1219
2015
Q4 		$13.4M Buy
2,209,570
+676,150
+44% +$4.68M ﹤0.01% 1213
2015
Q3 		$11.5M Sell
1,533,420
-210
-0% -$1.53K ﹤0.01% 1271
2015
Q2 		$10.2M Buy
1,533,630
+8,700
+0.6% +$59.5K ﹤0.01% 1344
2015
Q1 		$11.1M Buy
1,524,930
+117,010
+8% +$886K ﹤0.01% 1310
2014
Q4 		$11.2M Buy
1,407,920
+1,100
+0.1% +$9.34K ﹤0.01% 1293
2014
Q3 		$14.2M Buy
1,406,820
+83,030
+6% +$841K ﹤0.01% 1214
2014
Q2 		$14.6M Buy
+1,323,790
New +$14.4M ﹤0.01% 1214

Other funds holding ASPN

KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCMI
Oaktop Capital Management II Chatham, New Jersey $2.35B AUM 214.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
GKFF
George Kaiser Family Foundation Tulsa, Oklahoma $1.04B AUM 36.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

T. Rowe Price Associates's ASPN Position: Q2 2026 in Review

T. Rowe Price Associates increased its Aspen Aerogels (ASPN) stake by 21% in Q2 2026, buying an estimated $113K and bringing the position to 130,300 shares worth $827K. The position accounts for ﹤0.01% of the portfolio, ranked #2412.

T. Rowe Price Associates first reported a position in ASPN in Q2 2014 and has held it in 29 quarters since. The position peaked at $20.8M in Q3 2021. 179 funds tracked by Wall St. Rank hold ASPN as of Q2 2026.

  • T. Rowe Price Associates held 130,300 shares of Aspen Aerogels worth $827K as of Q2 2026.
  • T. Rowe Price Associates bought 23,000 Aspen Aerogels shares in Q2 2026, an estimated $113K.
  • Aspen Aerogels made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2412 holding.
  • T. Rowe Price Associates first reported a position in Aspen Aerogels in Q2 2014 and has held it in 29 quarters since.
  • T. Rowe Price Associates's Aspen Aerogels position peaked at $20.8M in Q3 2021.
  • 179 funds tracked by Wall St. Rank held Aspen Aerogels as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.